Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria

Tkachova, O.; Яковлєва, Л. В.; Mitkova, Zornitsa; Manova, Manoela; Savova, Alexandra; Petrova, Guenka

doi:10.1186/s12913-019-4736-3

Cited by 2 publications

(2 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that the most affordable treatment is a generic atorvastatin in Bulgaria and generic rosuvastatin in Ukraine. [ 47 ] Naumovska and colleagues evaluated the market share and utilization trends of statins in the Republic of Macedonia. They concluded that the statin use increased from 42.347 DDD/ thousand inhabitants per day (TID) in 2013 to 71.697 DDD/TID in 2016, although it is still lower in comparison to other European Union (EU) countries (1.1–2.5-fold) [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

The long-term effect of generic price competition on the Hungarian statin market

Répásy

Gazsó

Elmer

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background Generic competition is a vital health policy tool used in regulating the pharmaceutical market. Drug group HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase) inhibitors, widely known as “statins,” was the first drug group in Hungary in which generic prescriptions became mandatory. Our aim is to analyze the changes in the retail and wholesale margins through the generic competition regarding “statins”. Methods Data was derived from the nationwide pharmaceutical database of the Hungarian National Health Insurance Fund Administration, the only health care financing agency in Hungary. We observed the turnover data regarding the HMG-CoA-reductase inhibitor “statins” from 2010 through 2019. As the drugs under review have a fixed price point in Hungary, we effectively calculated the margins. Results In 2010, the consumer expenditure of statins was 30.7 billion HUF ($148 million), which decreased by 59%, to 12.5 billion HUF ($42.9 million) in 2019. In 2010, the annual health insurance reimbursement of statins was 23.7 billion HUF ($114 million), which underwent a 63% decrease to 8.6 billion HUF ($29.7 million) in 2019. In 2010, the DOT turnover was 287 million days, and it increased to above 346 million days for 2019, which reflects a 20% increase over the past nine years. The monthly retail margins decreased from 334 million HUF ($1.6 million), (January, 2010) to 176 million HUF ($0.61 million), (December, 2019). The monthly wholesale margins decreased from 96.3 million HUF ($0.46 million), (January, 2010) to 41.4 million HUF ($0.14 million), (December, 2019). The most significant downturn in margins was due to the introduction of the first two blind bids. The combined DOT turnover in reference to the examined 43 products consistently increased. Conclusions The decline in retail and wholesale margin and in health insurance expenditures was largely due to a reduction in the consumer price of generic medicines. DOT turnover of statins also increased significantly.

show abstract

Section: Discussionmentioning

confidence: 99%

The long-term effect of generic price competition on the Hungarian statin market

Répásy

Gazsó

Elmer

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…The fall in mortality among the elderly population may be explained by a large number of factors. The treatment of diseases that are the most common causes of death such as heart disease and stroke, new therapies for cancer (which is the second most frequent cause of death worldwide), socioeconomic conditions, access to medical care and medicinal products, nutrition, sanitation, community education, and preventative health programs altogether play a significant role in this process [ 39 , 40 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Healthcare Expenditures in Bulgaria

et al. 2022

Self Cite

View full text Add to dashboard Cite

The growth of public expenditure worldwide has set the priority on assessment of trends and establishment of factors which generate the most significant public costs. The goal of the current study is to review the tendencies in public healthcare expenditures in Bulgaria and to analyze the influence of the demographic, economic, and healthcare system capacity indicators on expenditures dynamics. A retrospective, top-down, financial analysis of the healthcare system expenditures was performed. Datasets of the National Statistical Institute (NSI), National Health Insurance Fund (NHIF), and National Center of Public Health and Analysis (NCPHA) were retrospectively reviewed from2014–2019 to collect the information in absolute units of healthcare expenditures, healthcare system performance, demographics, and economic indicators. The research showed that increasing GDP led to higher healthcare costs, and it was the main factor affecting the cost growth in Bulgaria. The number of hospitalized patients and citizens in retirement age remained constant, confirming that their impact on healthcare costs was negligible. In conclusion, the population aging, average life expectancy, patient morbidity, and hospitalization rate altogether impacted healthcare costs mainly due to the multimorbidity of older people and the rising need for outpatient hospital services and medications.

show abstract

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria

Cited by 2 publications

References 22 publications

The long-term effect of generic price competition on the Hungarian statin market

The long-term effect of generic price competition on the Hungarian statin market

Analysis of Healthcare Expenditures in Bulgaria

Contact Info

Product

Resources

About